What is the definition of Adult T-Cell Leukemia?

Adult T-cell leukemia/lymphoma (ATL) is is a rare and aggressive T-cell lymphoma that is linked to infection by the human T-cell lymphotropic virus 1 (HTLV-1). The exact mechanism by which HTLV-I infection causes the ATL is unknown. The clinical features of ATL include generalized swelling of the lymph nodes (lymphadenopathy), increased liver and spleen size (hepatosplenomegaly), immunosuppression, high levels of calcium in the blood, lytic bone lesions (spots that appear as “holes” on a standard bone x-ray), and skin lesions.  There are four basic clinical variants of ATL: acute (60% of cases), lymphomatous (20 % of cases), chronic (10% of cases) and smoldering (10% of cases). The best treatment for these patients is unclear and patients should be enrolled in clinical trials whenever possible. Medication may include CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone) or EPOCH (etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone). In some patients, a bone marrow transplant may be recommended.

What are the alternative names for Adult T-Cell Leukemia?

  • ATLL
  • Adult T-cell leukaemia
  • Adult T-cell leukaemia/lymphoma (HTLV-1 positive)
  • Adult T-cell lymphoma
  • Condition: Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia
  • Journal: JAMA
  • Treatment Used: Blinatumomab versus Standard Intensive Multidrug Chemotherapy before Allogeneic Hematopoietic Stem Cell Transplant
  • Number of Patients: 108
  • Published —
The study researched the use of blinatumomab versus chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia.
  • Condition: B-cell Malignancies, Mantle cell lymphoma, and Multiple Myeloma
  • Journal: Frontiers in immunology
  • Treatment Used: CAR T-Cell Therapy
  • Number of Patients: 0
  • Published —
This article discusses the use of CAR T-cell therapy in the treatment of patients with B-cell malignancies, mantle cell lymphoma, and multiple myeloma.
Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 1
  • Intervention Type: Drug, Genetic
  • Participants: 21
  • Start Date: September 1, 2021
Cell Therapy for High Risk T-Cell Malignancies Using CD7-specific CAR Expressed On Autologous T Cells (CRIMSON)